ProQR Therapeutics
PRQR
51 hedge funds and large institutions have $34.2M invested in ProQR Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 12 closing their positions.
165% more call options, than puts
Call options by funds: $284K | Put options by funds: $107K
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
1.47% less ownership
Funds ownership: 27.62% → 26.15% (-1.5%)
7% less funds holding
Funds holding: 55 → 51 (-4)
28% less capital invested
Capital invested by funds: $47.5M → $34.2M (-$13.3M)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$392K |
| 2 |
Squarepoint
New York
|
+$262K |
| 3 |
Two Sigma Advisers
New York
|
+$170K |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$151K |
| 5 |
Two Sigma Investments
New York
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.36M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$620K |
| 3 |
Morgan Stanley
New York
|
-$299K |
| 4 |
HF
HRT Financial
New York
|
-$293K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$215K |
PRQR Hedge Fund Activity: Q2 2023 in Review
51 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2023, worth a combined $34.2M — down 28% from $47.5M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PRQR and 8 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 12 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $392K. The largest seller was Millennium Management, cutting an estimated $1.36M.
- 51 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2023, down from 55 in Q1 2023.
- Funds reported $34.2M of ProQR Therapeutics stock for Q2 2023, down 28% quarter-over-quarter.
- 8 funds opened new ProQR Therapeutics positions in Q2 2023 and 12 closed out, a net change of -4 holders.
- The largest ProQR Therapeutics buyer in Q2 2023 was Renaissance Technologies, an estimated $392K added.
- The largest ProQR Therapeutics seller in Q2 2023 was Millennium Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q2 2023.